mirabegron OCAS

DRUG2 trials

Sponsors

Astellas Pharma Inc

Conditions

BioavailabilityHealthy SubjectsPharmacokineticsPharmacokinetics of Mirabegron

Phase 1

To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

CompletedNCT01478503

Astellas Pharma IncHealthy Subjects, Pharmacokinetics

Start: 2005-05-31End: 2005-10-31Updated: 2013-07-02

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

CompletedNCT01478529

Astellas Pharma IncBioavailability, Healthy Subjects, Pharmacokinetics of Mirabegron

Start: 2006-02-28End: 2006-03-31Updated: 2013-06-27

Related Papers

Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

2012-10-0174 citations